Table 5. Key results for second and third line use of fulvestrant.
|
Second line use of fulvestrant
|
Third line use of fulvestrant
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Cohort A (with fulvestrant) | Cohort B (without fulvestrant) | Difference | ICER* | Cohort A (with fulvestrant) | Cohort B (without fulvestrant) | Difference | ICER | |
| NSAI (anastrazole/ letrozole) | £1233 | £1233 | £0 | £1260 | £1260 | £0 | ||
| Fulvestrant | £2037 | £2037 | £755 | £755 | £0 | |||
| Exemestane | £472 | £725 | −£253 | £1296 | −£400 | |||
| Docetaxel | £4151 | £4572 | −£421 | £4345 | £4745 | −£400 | ||
| Capecitabine | £1120 | £1302 | −£182 | £1198 | £1382 | −£182 | ||
| BSC | £2713 | £3593 | −£880 | £2802 | £3857 | −£1055 | ||
| Cost per patient | £11 725 | £11 424 | £301 | £11 055 | £11 424 | −£370 | ||
| Mean survival (months) | 22.3 | 21.7 | 0.56 | 22.34 | 21.87 | 0.468 | ||
| Life years per patient | 1.86 | 1.81 | 0.05 | 1.86 | 1.82 | 0.04 | ||
| QALYs per patient | 1.18 | 1.14 | 0.04 | 1.178 | 1.142 | 0.036 | ||
| Incremental cost per LYG | — | £6500 | — | Cohort A dominant | ||||
| Incremental cost per QALY gained | — | £7300 | — | Cohort A dominant | ||||
LYG=life years gained; QALYs=quality-adjusted life years; ICER=incremental cost effectiveness ratio. *ICER values may not be directly derived from the figures presented in the table due to rounding errors. ICER values presented the nearest hundred pounds.